Toll-like receptors (TLRs) play an important role as
pattern-recognition receptors to sense and respond to pathogens. Our laboratory and others have shown recently that activation of TLR/MyD88 signaling through
vaginal administration of CpG
oligodeoxynucleotides, either singly or in combination with recombinant
glycoprotein from herpes simplex virus type 2 (HSV-2), confers immunity against
genital herpes infection. In this study, we have investigated the importance of the
myeloid differentiation factor 88 (MyD88), a critical adaptor
protein shared by all TLRs, in innate and acquired immunity against genital HSV-2
infection in mice. We demonstrate that MyD88 is essential for innate immune resistance against HSV-2. Thus, MyD88 deficient (MyD88(-/-)) mice show more vaginal HSV-2 titers, more rapid
disease progression and earlier death compared to C57Bl/6 mice following a vaginal challenge with high (9 x 10(4) PFU) or low (9 x 10(3) PFU) virus dose. In contrast, use of MyD88 appears dispensable for induction of HSV-specific serum
IgG antibody as well as local and systemic cell-mediated immune responses elicited by vaginal immunization with live attenuated
thymidine kinase-deficient HSV-2 (HSV-2 TK(-)). Importantly, and similar to immunized C57Bl/6 mice, immunized MyD88(-/-) mice were completely protected against subsequent vaginal challenge with a lethal dose of virulent strain of HSV-2. These results provide evidence that the adaptor
protein MyD88 is important for innate early control of genital HSV-2
infection, and that use of MyD88 is not required for induction of acquired immunity following vaginal immunization with HSV-2 TK(-).